Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) CEO David P. Schenkein sold 6,000 shares of the stock in a transaction that occurred on Wednesday, November 1st. The stock was sold at an average price of $63.85, for a total value of $383,100.00. The sale was disclosed in a filing with the SEC, which is available at this link.

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) traded up $4.48 during midday trading on Friday, hitting $66.49. The company had a trading volume of 354,476 shares, compared to its average volume of 410,645.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($1.59) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.78) by $0.19. The firm had revenue of $11.35 million for the quarter, compared to the consensus estimate of $10.85 million. Agios Pharmaceuticals had a negative return on equity of 69.64% and a negative net margin of 506.39%. The business’s quarterly revenue was up 26.4% compared to the same quarter last year. During the same period in the previous year, the business earned ($1.63) EPS. equities research analysts anticipate that Agios Pharmaceuticals, Inc. will post -6.89 earnings per share for the current year.

WARNING: This report was originally reported by American Banking News and is the property of of American Banking News. If you are reading this report on another publication, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The original version of this report can be read at https://www.americanbankingnews.com/2017/11/03/agios-pharmaceuticals-inc-agio-ceo-sells-383100-00-in-stock.html.

A number of institutional investors and hedge funds have recently made changes to their positions in AGIO. BlackRock Inc. lifted its holdings in Agios Pharmaceuticals by 8,463.5% during the 1st quarter. BlackRock Inc. now owns 2,167,074 shares of the biopharmaceutical company’s stock worth $126,556,000 after buying an additional 2,141,768 shares during the period. FMR LLC lifted its holdings in Agios Pharmaceuticals by 14.1% during the 2nd quarter. FMR LLC now owns 7,227,331 shares of the biopharmaceutical company’s stock worth $371,846,000 after buying an additional 895,584 shares during the period. Vanguard Group Inc. raised its position in shares of Agios Pharmaceuticals by 23.8% in the 2nd quarter. Vanguard Group Inc. now owns 3,214,770 shares of the biopharmaceutical company’s stock worth $165,401,000 after acquiring an additional 617,379 shares in the last quarter. Goldman Sachs Group Inc. raised its position in shares of Agios Pharmaceuticals by 748.0% in the 1st quarter. Goldman Sachs Group Inc. now owns 649,124 shares of the biopharmaceutical company’s stock worth $37,909,000 after acquiring an additional 572,579 shares in the last quarter. Finally, Janus Henderson Group PLC bought a new position in shares of Agios Pharmaceuticals in the 2nd quarter worth about $20,423,000. 93.46% of the stock is currently owned by hedge funds and other institutional investors.

AGIO has been the topic of a number of recent research reports. ValuEngine upgraded Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, September 1st. Royal Bank Of Canada started coverage on Agios Pharmaceuticals in a research note on Thursday, September 14th. They set an “outperform” rating and a $78.00 price objective on the stock. J P Morgan Chase & Co restated a “buy” rating and set a $76.00 price objective on shares of Agios Pharmaceuticals in a research note on Monday, September 18th. BidaskClub upgraded Agios Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, July 13th. Finally, SunTrust Banks, Inc. restated a “buy” rating and set a $80.00 price objective on shares of Agios Pharmaceuticals in a research note on Wednesday, October 4th. Three equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. Agios Pharmaceuticals presently has an average rating of “Buy” and a consensus target price of $75.70.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.

Insider Buying and Selling by Quarter for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.